How GenCART Began

GenCART was founded during the COVID-19 pandemic, when the global disruption exposed a critical weakness in the way advanced cell therapies were delivered. Centralized manufacturing centers—often thousands of miles away meant that patients with blood cancers faced delayed or canceled treatments, disrupted supply chains, and lost opportunities for timely care.

Witnessing these challenges, our team asked a simple but urgent question: 

How can we ensure that life-saving therapies remain accessible, even in times of crisis?

Out of that question, GenCART’s decentralized CAR-T manufacturing model was born. By bringing production closer to the patient—rather than 3,000 miles away—we aim to eliminate the bottlenecks of centralized systems, reduce time-to-treatment, and make next-generation cellular therapy available to every patient who needs it, wherever they are.

Reimagining CAR-T — Bringing the Cure Closer.

Sustainable Innovation: Build a resilient, decentralized system to ensure uninterrupted care—even in times of crisis.

Faster Access: Deliver CAR-T therapy locally, reducing wait times and eliminating long manufacturing delays.

Greater Safety: Use virus-free, nanotechnology-based methods to avoid insertional mutagenesis risks.

Expanded Reach: Bring advanced cellular therapies to community and regional centers worldwide.